Home' Australian Pharmacist : Australian Pharmacist June 2016 Contents Australian Pharmacist June 2016 I ©Pharmaceutical Society of Australia Ltd.
A new first for first aid
Australian-made Crystaderm® is a
trusted antiseptic to treat and prevent
infection in minor cuts, wounds and
abrasions. Crystaderm is formulated
with hydrogen peroxide which is well-
known for its antiseptic properties,
delivering strong protection against
skin infection. It has no antibiotic
resistance and so keeps on destroying
bacteria no matter how often it is
Crystaderm is preservative-free,
dries fast and vanishes as you apply,
thus eliminating staining on skin or
fabric. It is well tolerated with very few
1. Lipsky, B. A., and Hoey, C., Topical Antimicrobial Therapy
for Treating Chronic Wounds, 2009, 49:1541–1549.
Crystaderm® First Aid Cream
(Hydrogen Peroxide cream 1% w/w,
15g and 25g) is a first aid antiseptic
to help treat and prevent infection in
minor cuts, wounds and abrasions.
Always read the label. Use only as
directed. If symptoms persist see your
Bristol-Myers Squibb has welcomed
the approval of Opdivo (nivolumab),
as monotherapy, for the treatment
of patients with locally advanced
or metastatic non squamous non-
small cell lung cancer (NSCLC) who
have progressed on or after prior
chemotherapy. In patients with tumour
EGFR or ALK genomic aberrations,
Opdivo should be used after progression
on or after targeted therapy.
eligibility for treatment is not restricted
by specific biomarkers such as PD-L1.
More than 8,000 Australians die from
lung cancer each year which is more
than melanoma, prostate and breast
Lung cancer is
Australia’s leading cause of cancer death,
accounting for one in every five deaths
from cancer.3 With a 5-year survival rate of
14%, quality long term survival remains
elusive for many lung cancer patients.
CheckMate 057, a phase 3 trial, evaluated
the survival of patients with advanced
non squamous NSCLC who had
progressed during or after chemotherapy
The primary endpoint of this
study was overall survival (OS). Patients
were enrolled regardless of their PD-L1
status. In the trial, Opdivo significantly
improved median OS (12.2 months)
compared to docetaxel (9.4 months)
in previously treated advanced non
squamous NSCLC patients, with a 27%
reduction in the risk of death. At one year,
the OS rate for Opdivo patients was 51%
compared to 39% on docetaxel. At 18
months, the OS rate was 39% with Opdivo
compared to 23% with docetaxel.
Treatment related adverse events (Grade
3 or 4) were reported in 10% of patients
treated with Opdivo compared to 54% in
1. Opdivo Product Information. Feb 2016
2. Australian Institute of Health and Welfare. Cancer incidence
and mortality: change over time. At: www.aihw.gov.au/
cancer/rates-over-time/. (Accessed Feb 2016.)
3. Australian Institute of Health and Welfare. Cancer in Australia.
An Overview 2014. At: www.aihw.gov.au/WorkArea/
DownloadAsset.aspx?id=60129550202 (Accessed Feb 2016.)
4. Borghaei, H. CheckMate 057. Nivolumab versus Docetaxel in
Advanced Non-squamous Non-Small-Cell Lung Cancer. The
New England Journal of Medicine. 2015;373(17):1627–39 .
In late April another form of emergency
contraception became available to
Australian women of reproductive
age – EllaOne – an oral emergency
contraceptive pill with the active
ingredient ulipristal acetate. According
to MS Health EllaOne is more effective
than levonorgestrel for emergency
It should be taken
as soon as possible but no later than
120 hours (five days) after unprotected
sex or contraceptive failure.
chemical entity, EllaOne will be available
as a prescription medicine.
It is not listed
on the Pharmaceutical Benefits Scheme.
MS Health, a non-profit pharmaceutical
company and subsidiary of Marie Stopes
International, is the sponsor of EllaOne in
Ulipristal acetate is an orally-active
synthetic selective progesterone receptor
modulator that acts via high-affinity
binding to the human progesterone
receptor and was developed specifically
as an emergency contraceptive.
most commonly reported adverse
reactions to ulipristal acetate emergency
contraception were headache, nausea,
abdominal pain and dysmenorrhea, which
occur at similar rates to levonorgestrel.
Results from two independent
randomised controlled trials showed
the efficacy of ulipristal acetate to be
non-inferior to that of levonorgestrel in
women who presented for emergency
contraception between 0 and 72 hours
or 0 and 120 hours after unprotected
intercourse. When the data from the
two trials were combined via pooled
meta-analysis, the risk of pregnancy
was significantly reduced with ulipristal
acetate compared to levonorgestrel.
1. EllaOne Approved Product Information. Jan 2016.
2. Glasier et al., Ulipristal acetate versus levonorgestrel for
emergency contraception: a randomised non-inferiority trial
and meta-analysis, The Lancet, 2010;375:559–60.
3. Brache et al. Ulipristal acetate prevents ovulation more
effectively than levonorgestrel: analysis of pooled data
from three randomized trials of emergency contraception
regimens, Contraception, 2013;88:612–17 .
4. Glasier. The rationale for use of Ulipristal Acetate as first line in
emergency contraception: biological and clinical evidence,
Gynaecological Endocrinology, 2014;30(10):688–90 .
Links Archive Australian Pharmacist May 2016 Australian Pharmacist July 2016 Navigation Previous Page Next Page